EGFR mutation-specific antibodies in pulmonary adenocarcinoma: A comparison with DNA direct sequencing

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 4, 2012, Pages 356-362

  Ambrosini Spaltro, Andrea ^a   Campanini, Nicoletta ^a   Bortesi, Beatrice ^a   Azzoni, Cinzia ^a   Naldi, Nadia ^a   Ampollini, Luca ^a   Tiseo, Marcello ^a   Ardizzoni, Andrea ^a   Rusca, Michele ^a   Carbognani, Paolo ^a   Silini, Enrico M ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

antibodies; EGFR; lung adenocarcinoma

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E746; MONOCLONAL ANTIBODY L858R; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; DNA DIRECT SEQUENCE; DNA SEQUENCE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; ANTIBODIES; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTANT PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84862854126     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31823e064b     Document Type: Article

References (19)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354. (Pubitemid 40637826)
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139. (Pubitemid 38637993)
3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: 947-957.
5. Marchetti A, Normanno N, Pinto C, et al. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica. 2010;102:119-126.
6. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923. (Pubitemid 39665498)
7. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int. 2007;57:233-244.
8. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-3028.
9. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidiscipli-nary Classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
10. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17:206-218.
11. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12:169-176.
12. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010;16:3163-3170.
13. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol. 2010;5:1551-1558.
14. Kitamura A, Hosoda W, Sasaki E, et al. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res. 2010;16:3349-3355.
15. Simonetti S, Molina MA, Queralt C, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med. 2010;8:135.
16. Ilie MI, Hofman V, Bonnetaud C, et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch. 2010;457:483-495.
17. Kawahara A, Azuma K, Sumi A, et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer. 2011;74:35-40.
18. Tavassoli FA, Eusebi V. Staging of breast carcinoma and prognostic and predictive indicators. In: Tavassoli FA, Eusebi V, eds. AFIP Atlas of Tumor Pathology Tumors of the Mammary Gland. Washington, DC: American Registry of Pathology; 2009:123-148.
19. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochem-istry. Clin Cancer Res. 2010;16:1561-1571.